RANBAXY LAUNCHES OMEPRAZOLE 40 MG CAPSULES
Gurgaon, India; Princeton,
NJ – July 28, 2008 -- Ranbaxy Pharmaceuticals
Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories
Limited (RLL), Gurgaon, India announced today that under
an agreement with AstraZeneca Pharmaceuticals it has
launched an authorized generic of Omeprazole 40 mg Capsules
in the U.S. healthcare system. Omeprazole 40 mg is indicated
for the treatment of acid-related disease, including
gastric ulcer and Zollinger-Ellison syndrome. The most
common side effects of Prilosec® are headache, diarrhea
and abdominal pain. Prilosec® 40 mg had sales in
the U.S. market of $204.2 million (IMS: March 2008 MAT).
“We welcome the opportunity to market an authorized
generic of Omeprazole 40 mg capsules that will be commercialized
immediately to all classes of trade in the U.S. healthcare
system under the Ranbaxy label,” said Jim Meehan,
Vice President of Sales and Distribution for RPI. “We
will offer this product as an affordable and accessible
generic formulation to patients requiring this medication.”
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville,
Florida, is a wholly owned subsidiary of Ranbaxy Laboratories
Limited (RLL), India’s largest pharmaceutical
company. RPI is engaged in the sale and distribution
of generic and branded prescription products in the
U.S. healthcare system.
Ranbaxy Laboratories Limited, headquartered in India,
is an integrated, research based, international pharmaceutical
company producing a wide range of quality, affordable
generic medicines, trusted by healthcare professionals
and patients across geographies. Ranbaxy’s continued
focus on R&D has resulted in several approvals in
developed markets and significant progress in New Drug
Discovery Research. The Company’s foray into Novel
Drug Delivery Systems has led to proprietary "platform
technologies", resulting in a number of products
under development. The Company is serving its customers
in over 125 countries and has an expanding international
portfolio of affiliates, joint ventures and alliances,
ground operations in 49 countries and manufacturing
operations in 11 countries.
For further information, please contact:
|
